Canbex Therapeutics appoints CMO
This article was originally published in Scrip
Executive Summary
London, UK-based Canbex Therapeutics has named of Dr Alberto Lled� chief medical officer – effective 3 March 2014. Dr Lled� will lead Canbex's preparations for proof-of-concept trials for VSN16R, its orally active small molecule intended for the treatment of spasticity in multiple sclerosis. Dr Lled� is senior consultant neurologist at Clínica Creu Blanca, Barcelona, and previously spent sixteen years at Eli Lilly as global senior medical advisor and CNS clinical research physician for Europe. He replaces Dr Miroslav Ravic in the position at Canbex.